MarketResearchReports.Biz Recently Announced Research Report On "EpiCast Report: Chronic Obstructive Pulmonary Disease (COPD) - Epidemiology Forecast to 2023"
MarketResearchReports.Biz provide you pharmaceutical market research report "EpiCast Report: Chronic Obstructive Pulmonary Disease (COPD) - Epidemiology Forecast to 2023"
Chronic obstructive pulmonary disease (COPD), also known as chronic obstructive lung disease (COLD), is a condition characterized by difficulty breathing, shortness of breath, wheezing, chest tightness, and other respiratory symptoms that progress over time. The disease is often caused by smoking; however, long-term exposure to other lung irritants, such as pollution, smoke from vehicle emissions and power stations, chemical fumes, and dust, can also lead to the development of COPD. COPD is also a significant cause of morbidity and mortality, and the World Health Organization (WHO) predicts that it will be the third leading cause of death in the world by 2030.
In the 8MM, GlobalData epidemiologists forecast that the total prevalent cases of COPD will increase from 64,229,605 cases in 2013 to 73,794,089 cases in 2023 at an Annual Growth Rate (AGR) of 1.49%. GlobalData epidemiologists also forecast that the diagnosed prevalent cases of COPD will increase from 18,920,845 cases in 2013 to 21,789,454 cases in 2023 at an AGR of 1.52%. In the 8MM in 2013, 16.41% of the diagnosed prevalent cases of COPD were in GOLD Stage I, 24.66% were in GOLD Stage II, 29.09% were in GOLD Stage III, and 29.84% were in GOLD Stage IV. GlobalData epidemiologists estimated that 18,065,499 of the diagnosed prevalent cases of COPD in 2013 would have survived to the end of the year.
Download The sample Copy Of This Report: http://www.marketresearchreports.biz/sample/sample/501201
This analysis for COPD is a market-driven epidemiological report providing detailed segmentations of the COPD patient population, including the age- and sex-specific distribution of the total and diagnosed prevalent cases, the GOLD stage distributions for the total and diagnosed prevalent cases, the diagnosed prevalent cases that have comorbidities, and an estimation of the exacerbations and mortality for the forecast COPD patients. GlobalData epidemiologists also describe in detail the sources and methodology that were used in the forecast, thereby ensuring transparency of the forecasting process.
- The Chronic Obstructive Pulmonary Disease (COPD) EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for COPD in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Australia). It includes a 10-year epidemiological forecast of the total prevalent cases of COPD and total diagnosed prevalent cases of COPD, segmented by age and sex. Additionally it provides segmentation of diagnosed prevalent cases by severity using the GOLD standard.
- The COPD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.
Explore All Published Reports By Same Publisher @ http://www.marketresearchreports.biz/publisher/1
Reasons to buy
The COPD EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global COPD market.
- Quantify patient populations in the global COPD market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for COPD therapeutics in each of the markets covered.
- Identify the COPD comorbidities that are most important to your marketing plans